Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Lassen Therapeutics shares new data on LASN01's potential in treating Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease
Latest Hotspot
4 min read
Lassen Therapeutics shares new data on LASN01's potential in treating Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease
17 September 2023
Lassen Therapeutics is developing novel antibody treatments for fibro-inflammatory diseases and cancer, focusing on the IL-11R receptor (LASN01) and interleukin-18 binding proteins.
Read →
 Exploring Zaleplon's Revolutionary R&D Successes
Drug Insights
4 min read
Exploring Zaleplon's Revolutionary R&D Successes
17 September 2023
This article summarized the latest R&D progress of Zaleplon, the Mechanism of Action for Zaleplon, and the drug target R&D trends for Zaleplon.
Read →
Cystic Fibrosis Treatment Drug - CFTR Modulators
Cystic Fibrosis Treatment Drug - CFTR Modulators
17 September 2023
The CFTR protein is an ion channel mainly used to regulate the transepithelial movement of anions in mucus secretion tissues, thereby coordinating the balance of salt and fluid levels in mucus secretions.
Read →
Decoding Venetoclax: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
4 min read
Decoding Venetoclax: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
17 September 2023
This article summarized the latest R&D progress of Venetoclax, the Mechanism of Action for Venetoclax, and the drug target R&D trends for Venetoclax.
Read →
The primary endpoint achieved by FASENRA in the Phase III MANDARA trial for eosinophilic granulomatosis with polyangiitis
Latest Hotspot
4 min read
The primary endpoint achieved by FASENRA in the Phase III MANDARA trial for eosinophilic granulomatosis with polyangiitis
17 September 2023
Positive high-level results from AstraZeneca's MANDARA Phase III study revealed that FASENRA(benralizumab)
Read →
Nemesis of Hypercholesterolemia - CETP inhibitors
Nemesis of Hypercholesterolemia - CETP inhibitors
17 September 2023
CETP, or Cholesteryl Ester Transfer Protein, plays a crucial role in lipid metabolism within the human body.
Read →
 Deep Scientific Insights on Triazolam's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on Triazolam's R&D Progress, Mechanism of Action, and Drug Target
17 September 2023
This article summarized the latest R&D progress of Triazolam, the Mechanism of Action for Triazolam, and the drug target R&D trends for Triazolam.
Read →
MBX Biosciences declares encouraging data from a Phase 1 Multiple Ascending Dose study for MBX 2109
Latest Hotspot
3 min read
MBX Biosciences declares encouraging data from a Phase 1 Multiple Ascending Dose study for MBX 2109
17 September 2023
MBX Biosciences, Inc. released favorable outcomes from the Phase 1 trial's multiple ascending dose section for MBX 2109.
Read →
An In-depth Analysis of Tioconazole's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
4 min read
An In-depth Analysis of Tioconazole's R&D Progress and Mechanism of Action on Drug Target
17 September 2023
This article summarized the latest R&D progress of Tioconazole, the Mechanism of Action for Tioconazole, and the drug target R&D trends for Tioconazole.
Read →
Star of transcriptional pathway potential: CDK9 inhibitor
Star of transcriptional pathway potential: CDK9 inhibitor
17 September 2023
CDK9, also known as cyclin-dependent kinase 9, plays a crucial role in the regulation of gene expression and cell cycle progression in the human body.
Read →
Timolol: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Timolol: Detailed Review of its Transformative R&D Success
17 September 2023
This article summarized the latest R&D progress of Timolol, the Mechanism of Action for Timolol, and the drug target R&D trends for Timolol.
Read →
EyePoint Pharmaceuticals releases an encouraging safety update for EYP-1901 under PAVIA and DAVIO 2 Phase 2 Clinical Studies
Latest Hotspot
4 min read
EyePoint Pharmaceuticals releases an encouraging safety update for EYP-1901 under PAVIA and DAVIO 2 Phase 2 Clinical Studies
17 September 2023
EyePoint Pharmaceuticals, Inc., a company focused on improving life quality for severe eye condition patients, has revealed promising safety data for its key product candidate EYP-1901.
Read →